HIV antibody 04_A06 almost neutralises all strains
A newly discovered antibody, 04_A06, has shown unprecedented effectiveness against HIV, neutralising 98.5 percent of tested strains and permanently suppressing the virus in humanised mice.
List view / Grid view
A newly discovered antibody, 04_A06, has shown unprecedented effectiveness against HIV, neutralising 98.5 percent of tested strains and permanently suppressing the virus in humanised mice.
Researchers have discovered a surface protein that helps acute myeloid leukaemia cells evade the immune system, offering potential insights to aid the development of new treatments.
Analysing complex biologics is one of drug discovery’s biggest challenges. At Genentech, Rachel Shi is developing MS workflows that deliver clearer answers, faster.
Researchers at Mount Sinai have identified three antibodies that target mpox and prevent severe disease in vivo. The work positions A35-specific antibodies as candidates for therapeutic development.
Choosing the right bispecific antibody format can make or break your therapy’s success. This article explores how format impacts function, manufacturability and development strategy - helping you make the best choice from the start.
Discover the key scientific, strategic and manufacturing factors that could decide whether your bsAb succeeds in the clinic or stalls in development.
Bispecific T-cell engagers are advancing fast - but complexity still slows development. This article explores how data-driven, platform-based strategies are helping overcome design and manufacturing hurdles to bring these next-gen therapies to patients faster.
Recombinant antibody technology is redefining research standards - bringing biopharma-grade precision, consistency, and customisation to the lab. Discover how advances like Fc engineering and chimerisation are accelerating progress from basic discovery to clinical insight.
Standard antibody therapies bind their target and trigger a response. But what if the real breakthrough is designing antibodies that first recognise context before they act? This article looks at how bispecifics are becoming smarter, more selective and more precise.
Find out how dual-target ADCs and tumour-specific Treg depletion are shaping the next wave of targeted cancer therapies.
James Atwood, COO of Opentrons, shares how accessible lab automation is helping research teams tackle tighter budgets, faster timelines and complex discovery workflows.
Centauri Therapeutics has published data showing that CTX-09’s ability effectively clears drug-resistant Gram-negative bacteria through a novel dual mechanism, marking a promising development for new infection therapies.
While ADCs continue to attract attention in oncology, many developers remain focused on antibodies – overlooking the critical role of payload design. At Sygnature Discovery, Dr Joshua Greally is leading a shift in perspective, advocating for a payload-first approach through the company’s new platform, NewPath ADC. In this interview, he…
5 June 2025 | By WuXi Biologics
Stop costly biologic failures. This masterclass reveals high-throughput strategies to optimize antibody leads upfront.
Generative AI is broadening the boundaries of what is possible in drug discovery. In this article, Murat Tunaboylu, CEO and Co-founder of Antiverse, reveals how the zeitgeist technology is enabling scientists to tackle previously undruggable targets like GPCRs and ion channels to deliver patient impact faster.